Context: Obesity is associated with poor bone mineralization and quality. Fibroblast growth factor 23 (FGF23) plays an important role in skeletal physiology.
normal weight individuals, may be at increased risk for low-trauma extremity fractures, inferior bone quality, and lower bone formation (4) (5) (6) (7) (8) (9) . The reason for these findings is not well understood and is likely multifactorial; one key element likely involves secondary hyperparathyroidism and subsequent abnormal bone mineralization that stems from a higher prevalence of vitamin D deficiency (10, 11) .
Several humoral factors that may link adipose tissue to deleterious impacts on the skeleton have been noted, including proinflammatory cytokines and adipocytokines (12, 13) . It is notable that adipocytes and osteoblasts share a common precursor, the pluripotent mesenchymal stem cell, thereby providing a cellular link between adiposity and skeletal homeostasis (14) . Fibroblast growth factor 23 (FGF23) is a key regulator of phosphate and vitamin D metabolism and is a known predictor of metabolic bone disease in chronic kidney disease (CKD) (15) (16) (17) . Although there is no direct evidence that FGF23 is produced in adipose tissue, other members of the FGF family (factors 19 and 21) are expressed by adipocytes and may have roles in energy regulation (18, 19) . In addition, higher parathyroid hormone (PTH) levels, which are commonly observed in obesity, may promote higher FGF23 levels via direct PTH action and/or indirectly via upregulation of 1,25-dihydroxyvitamin D (1,25OH 2 D) (20, 21) . The actions of FGF23 include inhibition of 1,25OH 2 D synthesis and increase of phosphate excretion; therefore, excess FGF23 may interfere with bone mineralization by decreasing the availability of calcium and phosphate substrates.
In non-CKD populations, higher FGF23 levels have been associated with higher fracture risk (22) , and two relatively small studies have observed an independent association between adiposity and higher FGF23 levels in non-CKD individuals (23, 24) . These studies have raised the question of whether adipose tissue may promote an increase in FGF23 levels. A major limitation of the aforementioned studies was the incomplete assessment of notable regulators of bone and mineral metabolism that may have affected FGF23 and/or skeletal health, including PTH, vitamin D, and serum and urinary calcium and phosphate.
In this context, we hypothesized that FGF23 may be oversecreted in obesity and states of greater adiposity, even in the setting of normal kidney function. We tested this hypothesis by performing a cross-sectional study to assess whether greater adiposity was significantly associated with higher FGF23 levels, independent of other known regulators of FGF23 and mineral metabolism. We used crude measures of adiposity [body-mass index (BMI), waist circumference (WC), and waist-to-hip ratio (WHR)], as well as more sensitive assessments of adiposity [abdominal adipose tissue area measured by computed tomography (CT)], and accounted for the influences of estimated glomerular filtration rate (eGFR), calcium and phosphate balance, 25-hydroxyvitamin D (25OHD), and PTH.
Materials and Methods

Study population
The Multi-Ethnic Study of Atherosclerosis (MESA) is a prospective cohort study of 6814 community-living adults ages 45 to 84 years, which was established to study risk factors and progression of subclinical cardiovascular disease. Details of this cohort have been previously published (25) . Subjects were recruited from six centers across the United States (New York, New York; Baltimore, Maryland; Forsyth County, North Carolina; Chicago, Illinois; St. Paul, Minnesota; and Los Angeles, California). Institutional review boards approved the study at all sites, and participants provided informed consent.
At the first MESA examination, conducted from 2000 to 2002, 6814 participants were included and underwent assessments of demographic data, anthropometrics, medication use, and assessments of serum and urinary calcium and phosphate, 25OHD, PTH, and FGF23. For our current analyses, we included only those participants with data available for all these relevant mineral metabolites and excluded those with key data missing. Furthermore, we excluded any participant who may have had potentially unrecognized primary hyperparathyroidism (Ca .10.2 mg/dL with PTH .65 pg/mL). Given that chronic kidney disease is a strong predictor of FGF23, we excluded participants with an eGFR ,60 mL/min/1.73m 2 to reduce confounding. After exclusions, the final sample size for this study was 5610 participants (Fig. 1) .
Among this population of 5610, a subset of 1313 participants underwent abdominal CT with assessment of total, visceral, and subcutaneous adipose tissue areas, as previously described (26) . CT scans were performed during MESA examinations 2 or 3, which occurred between 2002 and 2005. We excluded any participant who had missing data for the assessments of total, subcutaneous, or visceral adipose area, leaving a final sample size of 1313 participants who had CT measurement and quantification of adipose tissue areas (Fig. 1) .
Assessment of demographic and anthropometric variables
Questionnaires and standardized interviews administered by study coordinators were completed by all participants to obtain demographic, medical history, and medication use data. Anthropometric protocols were standard across sites (27) 2 ) of two CT slices, one at the L3/L4 junction and the second just superior to the L3/L4 junction. Subcutaneous and visceral adipose tissue areas were calculated separately, as previously described with respect to the MESA cohort (26) . Total abdominal adipose tissue (TAAT) area included subcutaneous adipose tissue (SAT) area, visceral adipose tissue (VAT) area, and a small amount of intermuscular adipose, collected during the same scan.
Laboratory measurements
All serum and urine samples at examination 1 were collected after an overnight fast, in the morning before 10 AM, and stored at 280°C prior to analysis. Serum intact FGF23 was measured using the Kainos sandwich immunoassay (Kainos, Tokyo, Japan), which measures the full-length (intact) FGF23 molecule (28) . The interassay coefficients of variation of standardized highand low-control samples were 6.7% and 12.4%, respectively (29) . Intact serum PTH concentrations were measured at the University of Washington using the Beckman-Coulter Dx1 automated twosite immunoassay (Beckman-Coulter, Brea, CA), with coefficients of variation of 6.1% at 30.1 pg/mL and 3.4% at 94.5 pg/mL (30) . Annualized 25OHD measurements were estimated using a cosinor model from single measurements to adjust for seasonal variations in 25OHD to estimate year-long 25OHD status. This model has been validated using longitudinal 25OHD measurements within the MESA population, as previously described (31) , with low sample coefficient of variation of 11.8% at 24.8 ng/mL and 8.5% at 7.0 ng/mL (31) . Serum creatinine was used to estimate eGFR by the CKD Epidemiology Collaboration (CKD-EPI) Equation (32) . Serum and urinary calcium and serum and urinary phosphate were measured as previously described (33) . Fractional excretion of phosphate was calculated from the serum and urinary measures of phosphate and creatinine.
Statistical analysis
Our primary analysis assessed the association between BMI and FGF23 levels (n = 5610). Secondary analyses using WC and WHR, instead of BMI, were also performed; in addition, we assessed the association of the more specific measure of adiposity by CT measurements with FGF23 in the subset of participants who had undergone CT examination (n = 1313).
We describe all study variables as means with standard deviations or counts with percents. We compared the mean values of FGF23 and other markers of mineral metabolism across BMI categories and quartiles of WC, WHR, and abdominal adiposity area using unadjusted trend analysis. Multivariable linear regression was used to assess the independent association between the predictors (BMI, WC, WHR, and adipose tissue area as continuous variables) and the outcome (FGF23) with adjustments for relevant demographic and socioeconomic covariates, as well as notable regulators of bone and mineral metabolism that may represent confounders or predictors of FGF23. Model A included adjustment for age, ethnicity, sex, eGFR, urine albumin-to-creatinine ratio, hyper- (35)], use of antidiabetic medications (Y/N), education level (no schooling though grade 11, or completed high school/through some college completed, or technical school certificate through graduate/professional school degree), cigarette smoking status (never, former, current), and physical activity (reported physical activity hours per week). We adjusted for both eGFR and urine albumin-to-creatinine ratio to account for mild forms of kidney dysfunction that may be present even with eGFR $ 60. Model B included adjustment for variables in model A, as well as the biochemical parameters of mineral metabolism: PTH, 25OHD, serum calcium, and urinary calcium-to-creatinine ratio. Model C adjusted for variables in models A and B, as well as serum phosphate and urinary fractional excretion of phosphate. We considered models B and C to be exploratory, given that some of these biochemical parameters may be involved as mediators in a potential causal pathway linking FGF23 with adiposity (especially phosphate metabolism). Univariate relationships between covariates and FGF23 are shown in Supplemental Table 1 . We also compared the mean values of FGF23 and other markers of mineral metabolism by race/ ethnicity, and tested the interaction of both race/ethnicity and sex on the association of adiposity with FGF23. FGF23 was not normally distributed and therefore was log-transformed in linear regression models. Beta coefficients were exponentiated and reported as percent difference in FGF23 per specified unit of adiposity measure.
We used SAS version 9.4 (SAS Institute, Cary, NC) for all statistical analyses. A two-tailed P value of ,0.05 was used to indicate statistical significance.
Results
Study population
The mean age of the total study population was 60.8 (9.9) years, 52.8% were women, and the mean BMI was The characteristics of the subset of participants who underwent CT with abdominal adipose tissue area measurements were similar to those of the total study population (Table 1) , although notably, there were minor differences in racial distribution, diabetes status, and values of BMI, WC, and WHR.
Crude measures of adiposity, FGF23, and mineral metabolism
Higher BMI was associated with lower 25OHD, lower serum calcium and urinary calcium excretion, and higher PTH levels ( Table 2 ). FGF23 levels were significantly higher across BMI categories despite the fact that eGFR did not decline (36) and serum phosphate did not increase. These findings were recapitulated when examined across WC and WHR quartiles; higher WC and WHR were associated with higher FGF23 despite lower serum phosphate, higher fractional excretion of phosphate, and no difference in eGFR (Supplemental Tables 2 and 3) .
We assessed the independent association between BMI (as a continuous variable) and FGF23 levels. BMI was positively associated with FGF23 levels, independent of notable demographic and socioeconomic covariates, but also independent of other regulators of FGF23 and bone and mineral metabolism ( Table 3 ). The fully adjusted effect estimate suggests that for a 10 kg/m 2 increase in BMI, there is a 7.2% higher FGF23. The fully adjusted (model C) R2 was 9%, and BMI accounted for 1.1% of this variance. We observed a similar independent association between higher WC and WHR and higher FGF23 levels (Supplemental Table 4 ).
White ethnicity was associated with higher FGF23, lower eGFR, and highest fractional excretion of phosphate than other ethnic groups (Supplemental Table 5 ). Values are mean (standard deviation), unless otherwise specified.
Abbreviation: Cr, creatinine.
However, there was no significant heterogeneity between BMI and FGF23 levels by race/ethnicity (Supplemental Table 6 ). In addition, there was no significant heterogeneity between BMI and FGF23 levels by sex (Supplemental Table 7 ).
Abdominal adipose tissue area, FGF23, and mineral metabolism We repeated our investigations using the more refined measures of abdominal adiposity obtained via CT. Higher areas of TAAT were associated with higher BMI (correlation r = 0.81) (Table 4) . Notably, there were large overlaps in the BMI ranges for each quartile of TAAT, underscoring the discrepancy between abdominal adiposity measures by CT and the crude measure of BMI. Higher TAAT was associated with lower 25OHD, lower urinary calcium excretion, and higher PTH levels, again suggesting a vitamin D deficiency and secondary hyperparathyroidism with higher adipose tissue burden. FGF23 was again significantly higher with adiposity, and this observation was despite the fact that serum phosphate levels were lower, fractional excretion of phosphate was higher, and eGFR was no different with higher abdominal adiposity (Table 4) .
The independent association between TAAT (as a continuous variable) and FGF23 levels was evaluated using adjusted linear regression models. A positive association between TAAT and FGF23 remained statistically significant following adjustment for important confounders of FGF23 and bone and mineral metabolism. In the fully adjusted model, there was a 3.1% higher FGF23 per standard deviation of TAAT area (Table 5) . We also examined whether specific depots of abdominal adipose tissue (SAT or VAT) may play a specific role in this relationship and observed no substantial differences by adipose tissue type (Table 5) .
Discussion
In a large community-based cohort with normal eGFR, we observed significantly higher FGF23 levels with adiposity, as assessed by crude measures such as BMI, WC, and WHR, as well as by more refined measurements with abdominal CT. These observations were independent of known determinants and confounders of FGF23. Low eGFR and high phosphate levels are traditionally considered to stimulate FGF23; however, we observed that eGFR did not decline and serum phosphate levels tended to be lower with higher abdominal adiposity, suggesting that higher FGF23 levels with greater degrees of adiposity FGF23 is a phosphaturic hormone that was initially identified as a key regulator of phosphate metabolism (37) and is most extensively understood and studied within the context of CKD. FGF23 increases significantly with declining eGFR and subsequent increases in serum phosphate; its phosphaturic effect may be considered as serving as a physiological "brake" on serum phosphate accumulation. In addition to increasing renal phosphate excretion, FGF23 also inhibits 1-a hydroxylase and stimulates 24-hydroxlyase, acting to reduce activated vitamin D (i.e., 1,25OH 2 D) concentrations. Given that 1,25OH 2 D enhances intestinal phosphate absorption, FGF23 suppression of 1,25OH 2 D production leads to further reductions in serum phosphate. Our observation of normal eGFR and stable to lower serum phosphate with higher adiposity would be expected to be associated with lower FGF23. Therefore, our contrary finding of higher FGF23 levels, despite these physiologic suppressants, may suggest that the high adipose tissue milieu, or adipose tissue itself, may induce increased secretion (or decreased degradation) of FGF23. It is important to note that in our non-CKD population, the observed changes in FGF23 with adiposity were of a much smaller magnitude than those seen in CKD (38) , suggesting that the mechanisms for higher FGF23 with adiposity may be distinct from those stimulating FGF23 in the setting of declining eGFR.
There are several hypotheses for why FGF23 may be higher with higher adiposity in a non-CKD population. Values are mean (standard deviation), unless otherwise specified. P values are linear trend across categories.
Abbreviation: Cr, creatinine. a Reported as mean with standard deviation and median with interquartile range (25th to 75th percentile). Higher PTH levels as a result of secondary hyperparathyroidism may stimulate 1-a hydroxylase, thereby increasing 1,25OH 2 D production. FGF23 expression is upregulated by 1,25OH 2 D (20); therefore, secondary hyperparathyroidism in obesity may indirectly increase FGF23 via its stimulation of 1,25OH 2 D production. Moreover, there is evidence that PTH may directly stimulate FGF23 production via PTH 1 receptor signaling in whole bone and osteocytes, although these data are limited to mouse models (21, 39) .
Adipose tissue expresses and secretes numerous other hormones that have been linked to FGF23 production (40) , providing other potential explanations for our findings. It is notable that the other members of the FGF family to which FGF23 belongs have been shown to be produced in adipose tissue and have important roles in energy metabolism; FGF21 is produced by adipocytes, among other tissues (18) , and contributes to thermogenesis and fatty acid storage (19) . There are also potential immunological roles of FGF23; its expression has been noted in mouse thymus, as well as dendritic cells and macrophages (41) , which are increased in proinflammatory visceral adipose tissue. Furthermore, higher levels of aldosterone have been described in overweight individuals (42) and those with higher VAT (43) . In a mouse model, administration of aldosterone increased FGF23 transcription by osteoblasts (44); thus, higher FGF23 with adiposity may also be related to renin-angiotensin-aldosterone system dysregulation. It is notable that we did not find a significant difference in the association of FGF23 with adiposity by specific adipose depot (i.e., SAT vs VAT), in contrast with other studies that have shown a more defined correlation between skeletal disease and VAT (45) . Lastly, leptin, which is typically increased in obesity as a result of leptin resistance, may play a role as well; in ob/ob mice, infusion of leptin markedly increased bone FGF23 expression (46) .
Whether higher FGF23 levels associated with adiposity have a clinical impact on skeletal health in obesity is yet to be determined. It is plausible that higher FGF23 levels in obesity negatively affect bone health via inhibition of 1,25OH 2 D activity and promotion of phosphaturia, two actions that can result in a deficiency in calcium and phosphate substrates that are needed for bone mineralization. This, compounded by the mineralization defects related to higher PTH in obesity, may provide a mechanism that explains adverse skeletal health in this population.
Beyond skeletal health, evidence linking higher FGF23 levels with cardiovascular disease and mortality (29, 47, 48 ) is growing, even in the absence of CKD. Given the already increased cardiovascular risk in obesity, FGF23 may play a role as dual offender in this population, negatively affecting not only skeletal health, but also cardiovascular health.
Strengths and limitations
Our study sample was relatively large, and included detailed measurements of bone and mineral metabolism and adiposity. In particular, we had specific measurements of nearly every known determinant of FGF23 to assess independent relationships between adiposity and FGF23 levels. In addition to BMI, WC, and WHR, which are relatively crude measures of adiposity, we were able to use the refined measure of abdominal adipose tissue areas derived from CT to strengthen and validate our observations.
Our study did have several important limitations that should be noted. The cross-sectional nature of this study design precludes us from concluding causality or directionality. Although significant and independent of numerous potential confounders, the effect estimates for the absolute relationships between adiposity and FGF23, as well as the variance in FGF23 explained by adiposity in the models, were relatively small. However, because these differences were in a population with normal kidney function, in which the deleterious impact of FGF23 is rarely studied, it may be premature to discount the size of these observed effects. Furthermore, the cross-sectional nature of the effect estimates prevents us from assessing the consequences of small but chronically higher FGF23 levels over time. We have presented potential explanations for the positive association of adiposity with FGF23 as being caused by excess adiposity. However, it is possible that FGF23 itself may promote adiposity, via increasing insulin resistance, for example, although evidence for this is currently lacking. Longitudinal studies may help to differentiate the direction of causality of our findings. In addition, all of our study measurements were performed at examination 1, except for the measurements of abdominal adiposity by CT, which were performed at examinations 2 or 3. However, we used the CT measurements as a cross-sectional snapshot to validate our findings with BMI, and in this regard, our two analyses were complementary and consistent. We did not have measures of serum 1,25OH 2 D or detailed information regarding dietary intake; however, the availability of PTH, as well as serum and urinary calcium and phosphate levels, should have accounted for the actions of 1,25OH 2 D and integrated dietary intake. Other studies have investigated the relationship between dietary intake and FGF23 levels (49) . Last, we cannot extend these findings to clinical outcomes related to skeletal health, such as bone mineral density and fracture; further study is needed to do so.
In summary, we observed that higher adiposity, as measured by BMI and abdominal adipose area according to CT, was independently associated with higher FGF23 levels in a large cohort of participants with normal eGFR. Higher FGF23 activity with greater adipose tissue burden may provide an additional explanation for the increased adverse skeletal outcomes seen in obesity. Further studies are needed to better understand the causes and consequences of high FGF23 in states of greater adiposity.
